<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893395</url>
  </required_header>
  <id_info>
    <org_study_id>TVA_IRBNetID_1614352</org_study_id>
    <nct_id>NCT04893395</nct_id>
  </id_info>
  <brief_title>Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans</brief_title>
  <official_title>Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auburn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tuscaloosa Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Auburn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the prevalence of veterans with major depressive&#xD;
      disorder (MDD) who are being treated with a medication that has current Clinical&#xD;
      Pharmacogenetics Implementation Consortium (CPIC) or Pharmacogenomics Knowledgebase&#xD;
      (PharmGKB) actionable recommendations that have a pharmacogenomic variation that impacts the&#xD;
      safety or efficacy of the subject medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pharmacogenomic variation with actionable recommendations for medications currently utilized</measure>
    <time_frame>At enrollment</time_frame>
    <description>A medication history will be conducted at enrollment to ensure patient meets criteria for enrollment. Patients will provide a saliva sample at this timepoint. The rate of pharmacogenomic variation will be calculated based on current medications at enrollment; however, the pharmacogenomic screening panel may take up to 6 weeks to return to the patient and investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of pharmacogenomic variation with actionable recommendations for all actionable medications</measure>
    <time_frame>At enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental health disease state control/progression utilizing disease state-specific validated tools</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
    <description>Validated, disease state-specific tools will be utilized to assess control or progression. Specifically, depression control will be assessed utilizing PHQ-9 as documented within the chart. This will be assessed via retrospective chart review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication-related costs</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
    <description>Claims data will be used to assess medication-related costs at specific time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication-related adverse events</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of primary care, mental health provider, mental health pharmacist, specialist, and emergency room visits and hospitalizations</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported medication adherence and reasons for non-adherence</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported reasons for non-adherence</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pharmacogenomic recommendations made and accepted</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of pharmacogenomic recommendations made and accepted</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-pharmacogenomic recommendations made and accepted</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of non-pharmacogenomic recommendations made and accepted</measure>
    <time_frame>3-, 6-, and 12-months post-recommendation via retrospective chart review</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pharmacogenetics</condition>
  <condition>Depressive Disorder, Major</condition>
  <condition>Medication Therapy Management</condition>
  <arm_group>
    <arm_group_label>Pharmacogenomic Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenomic Screening</intervention_name>
    <description>First telehealth appointment:&#xD;
Pharmacogenomics education and informed consent&#xD;
Medical history&#xD;
Sample collection&#xD;
Second telehealth appointment:&#xD;
Results of pharmacogenomic testing&#xD;
Utility and limitations of pharmacogenomic testing&#xD;
Patient-specific potential impacts on current or future medication therapies&#xD;
Answering of patient questions&#xD;
Referral to mental health provider(s) for treatment-specific recommendations</description>
    <arm_group_label>Pharmacogenomic Screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 19 years&#xD;
&#xD;
          2. Prescribed at least one chronic medication for mental health which is considered&#xD;
             pharmacogenomically actionable, as defined above (amitriptyline, doxepin, imipramine,&#xD;
             nortriptyline, citalopram, escitalopram, fluvoxamine, paroxetine, sertraline, or&#xD;
             venlafaxine).&#xD;
&#xD;
          3. Diagnosis of major depressive disorder (MDD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is a prisoner or is under a court order for treatment as part of a sentence or&#xD;
             incarceration&#xD;
&#xD;
          2. Persistent medication non-adherence for reasons not potentially linked to&#xD;
             pharmacogenomic variation (e.g. inability to obtain medications due to cost;&#xD;
             non-adherence due to cognitive impairment)&#xD;
&#xD;
          3. Individuals receiving mental health treatment/care from a non-VA facility&#xD;
&#xD;
          4. Individuals who are terminally ill&#xD;
&#xD;
          5. Inability to communicate in and/or understand English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly B Lloyd, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Auburn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney S Watts Alexander, Pharm.D.</last_name>
    <phone>3348441230</phone>
    <email>csw0015@auburn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly B Lloyd, Pharm.D.</last_name>
    <phone>3348444099</phone>
    <email>lloydkb@auburn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tuscaloosa VAMC</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Courtney SW Alexander, Pharm.D.</last_name>
      <phone>3348441230</phone>
      <email>csw0015@auburn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Garrett B Aikens, Pharm.D.</last_name>
      <phone>2055542000</phone>
      <phone_ext>2948</phone_ext>
      <email>garrett.aikens@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Garrett B Aikens, Pharm.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courtney S Watts Alexander, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courtney E Gamston, ScM, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberly B Lloyd, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auburn University</investigator_affiliation>
    <investigator_full_name>Courtney Watts Alexander</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

